Combination therapy with oncolytic viruses and immune checkpoint inhibitors in head and neck squamous cell carcinomas: an approach of complementary advantages

Hui Dong, Mengli Li, Chen Yang, Wei Wei, Xianglei He, Gang Cheng, Shibing WangCancer 2023 · DOI

Abstract

Squamous cell carcinomas are the most common head and neck malignancies. Significant progress has been made in standard therapeutic methods combining surgery, radiation, and chemotherapy. Nevertheless, the 5-year survival rate remains at 40-50%. Immune checkpoint inhibitors (ICIs) are a new strategy for treating head and neck squamous cell carcinomas (HNSCCs). Still, the overall response and effective rates are poor, as HNSCCs are 'cold' tumors with an immunosuppressive tumor microenvironment (TME), limiting ICI's beneficial effects. In this case, transforming the tumor suppression microenvironment before using ICIs could be helpful. Oncolytic viruses (OVs) can transform cold tumors into hot tumors, improving the situation. Talimogene laherparepvec (T-VEC), oncolytic immunotherapy authorized for advanced melanoma, also showed good safety and antitumor activity in treating head and neck cancer and pancreatic cancer. In combination with pembrolizumab, T-Vec may have more anticancer efficacy than either drug alone. Therefore, understanding the mechanisms underpinning OVs and their potential synergism with ICIs could benefit patients with HNSCC.

Introduction: The Challenge of "Cold" Tumors in HNSCC

Head and neck squamous cell carcinoma (HNSCC) remains a significant global health challenge, with a stagnant 5-year survival rate of approximately 40–50%. While the advent of Immune Checkpoint Inhibitors (ICIs), such as those targeting PD-1 or CTLA-4, has transformed the landscape of oncology, their efficacy in HNSCC has been limited.

The primary obstacle is the Tumor Microenvironment (TME). HNSCCs are frequently characterized as "cold" tumors—immunologically quiet environments lacking significant tumor-infiltrating lymphocytes (TILs) and dominated by immunosuppressive cells. Because ICIs function by "unleashing" an existing immune response, they are often ineffective in these "cold" environments. To improve outcomes, researchers are exploring ways to transform the suppressive TME into a pro-inflammatory "hot" environment.

Mechanisms of Oncolytic Virotherapy

Oncolytic viruses (OVs) are a promising class of biological agents that selectively infect and replicate within cancer cells. This review identifies three primary mechanisms through which OVs exert their anti-tumor effects:

  1. Direct Oncolysis: The virus replicates until the host cancer cell bursts, physically destroying the tumor.
  2. Immune Induction: The lysis of tumor cells releases Pathogen-Associated Molecular Patterns (PAMPs) and Tumor-Associated Antigens (TAAs). These act as "danger signals" that alert and recruit the systemic immune system.
  3. Vascular Destruction: OVs can disrupt the tumor's nutrient supply lines by inducing the death of vascular endothelial cells within the tumor.
Mechanisms of action for oncolytic viruses (OVs) in tumor therapy, including direct lysis, systemic immune induction, and anti-angiogenesis.

Synergistic Potential: Turning "Cold" to "Hot"

The most critical insight of this combination therapy is the "complementary advantage" between OVs and ICIs. OVs serve as a biological bridge, acting as a spark that turns "cold" tumors "hot." By inducing inflammation and recruiting T-cells to the tumor site, OVs prepare the "battlefield" for ICIs.

Furthermore, OVs often cause tumors to upregulate their expression of PD-L1. While PD-L1 is typically a mechanism for immune evasion, in the context of combination therapy, it provides more targets for ICI drugs to bind to, thereby enhancing treatment efficacy. This synergy addresses different stages of the Cancer-Immunity Cycle: OVs facilitate the "priming" and "trafficking" phases, while ICIs enhance the "recognition" and "killing" phases.

The cancer-immunity cycle and the points of intervention for various immunotherapies, highlighting how OVs and ICIs work at different stages.

Clinical and Preclinical Evidence

The paper reviews several landmark studies that demonstrate the potential of this combined approach:

  • T-VEC Synergy: In a Phase 1b trial for advanced melanoma, the combination of the oncolytic virus T-VEC and Pembrolizumab achieved a 62% Objective Response Rate (ORR), with a 33% complete response rate—significantly higher than monotherapy results.
  • HNSCC Trials: Trials like Checkmate-141 (Nivolumab) have shown improved median overall survival in recurrent/metastatic HNSCC (7.5 months vs. 5.1 months with standard therapy).
  • Preclinical Models: In aggressive peritoneal cancer models, combining an oncolytic vaccinia virus with anti-PD-L1 treatment led to a cure rate exceeding 40%.

Importantly, clinical data suggests that the combination of OVs and ICIs is generally well-tolerated, with side effects primarily limited to transient "flu-like" symptoms associated with viral activity.

Future Directions and Limitations

Despite the clear promise of "complementary advantages," several hurdles remain for widespread clinical adoption:

  • Delivery Logistics: Most current OVs require direct intratumoral injection, which is challenging for deep-seated or inaccessible tumors.
  • Antiviral Immunity: The systemic immune system may neutralize the virus before it reaches the tumor, particularly during intravenous delivery.
  • Optimization: Determining the optimal sequencing of therapies (e.g., whether to administer the virus before or concurrently with ICIs) remains a key area of investigation.

The authors conclude that future research must focus on advanced viral engineering to shield OVs from the systemic immune response and improve delivery to metastatic sites, ultimately maximizing the synergistic potential of this dual-modality approach.

Summary updated

Abstract

Squamous cell carcinomas are the most common head and neck malignancies. Significant progress has been made in standard therapeutic methods combining surgery, radiation, and chemotherapy. Nevertheless, the 5-year survival rate remains at 40-50%. Immune checkpoint inhibitors (ICIs) are a new strategy for treating head and neck squamous cell carcinomas (HNSCCs). Still, the overall response and effective rates are poor, as HNSCCs are 'cold' tumors with an immunosuppressive tumor microenvironment (TME), limiting ICI's beneficial effects. In this case, transforming the tumor suppression microenvironment before using ICIs could be helpful. Oncolytic viruses (OVs) can transform cold tumors into hot tumors, improving the situation. Talimogene laherparepvec (T-VEC), oncolytic immunotherapy authorized for advanced melanoma, also showed good safety and antitumor activity in treating head and neck cancer and pancreatic cancer. In combination with pembrolizumab, T-Vec may have more anticancer efficacy than either drug alone. Therefore, understanding the mechanisms underpinning OVs and their potential synergism with ICIs could benefit patients with HNSCC.
BibTeX
@inproceedings{dong2023combination,
  author = {Hui Dong and Mengli Li and Chen Yang and Wei Wei and Xianglei He and Gang Cheng and Shibing Wang},
  title = {{Combination therapy with oncolytic viruses and immune checkpoint inhibitors in head and neck squamous cell carcinomas: an approach of complementary advantages}},
  booktitle = {Cancer},
  year = {2023},
  doi = {10.1186/s12935-022-02846-x},
}
Figure